argenx SE (LON:0QW0)

London flag London · Delayed Price · Currency is GBP · Price in EUR
510.80
+3.45 (0.68%)
At close: Jun 5, 2025
46.95%
Market Cap 26.27B
Revenue (ttm) 2.05B
Net Income (ttm) 823.61M
Shares Out n/a
EPS (ttm) 12.34
PE Ratio 31.90
Forward PE 37.51
Dividend n/a
Ex-Dividend Date n/a
Volume 4,157
Average Volume 20,698
Open 508.00
Previous Close 507.35
Day's Range 500.60 - 510.80
52-Week Range 342.90 - 656.80
Beta 0.04
RSI 47.63
Earnings Date May 8, 2025

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 1,599
Stock Exchange London Stock Exchange
Ticker Symbol 0QW0
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.